Dear Editor, Recently, we read with great interest the article "Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk" published in November 2011 in "Genetics and Molecular Research" (Li et al., 2011) . Li et al. (2011) performed a meta-analysis to make an estimation of the association between codon 72 polymorphism of the p53 gene and prostate cancer risk. They concluded that there is no association between p53 codon 72 polymorphism and prostate cancer risk both in Caucasian and Asian populations.
Nevertheless, some methodological issues need to be addressed concerning the metaanalysis by Li et al. (2011) . Importantly, using the same search strategy and end-of-search date as those of Li et al. (2011) , we have located four relevant studies in Pubmed database with a total of 544 prostate cancer patients and 1005 controls (Wu et al., 1995; Hirata et al., 2007 Hirata et al., , 2009 Xu et al., 2010) (Table 1) , which were not included in the meta-analysis even though they were consistent with the search criteria. Among them, two articles (Hirata et al., 2007 (Hirata et al., , 2009 had duplicate data of cases and controls, so we selected the most complete and larger study (Hirata et al., 2007) . Finally, three newly additional studies should be included.
Secondly, one recent study by Ricks-Santi et al. (2010) reported the relationship between p53 Pro72Arg polymorphism and prostate cancer in men of African descent. However, Li et al. (2011) considered the race as Caucasian populations not Africans.
Moreover, in the statistical analysis section, the authors gave a P value <0.10 for the Q-statistic that indicated heterogeneity among the studies. Actually, a P value <0.05 rather than <0.10 for the Q-statistic indicates heterogeneity across studies (Xu et al., 2012) .
Taking into account the aforementioned methodological considerations, we put all studies into a new meta-analysis, including three large eligible studies, and we observed that codon 72 polymorphism of the p53 gene was also not significantly correlated with prostate risk: Pro-allele 2 = 64.3%). Similar associations were also detected in subgroups by race and source of controls.
In conclusion, the results of the study by Li et al. (2011) should be interpreted with caution. To reach a definitive conclusion, further studies based on a larger sample size are still needed to assess the association of p53 gene codon 72 polymorphisms and serum expression with prostate cancer risk, especially in African and Caucasian populations. We believe that our remarks will contribute to more accurate elaboration of the results presented by Li et al. (2011) .
